AmpliPhi Biosciences wins UK grant to develop antimicrobials
Next generation, specific, natural antimicrobials for personal care
Biocontrol Ltd, a wholly owned subsidiary of AmpliPhi Biosciences Corp has been awarded UK government funding through the Technology Strategy Board for R&D using genomics-based technologies. The project, part of a £4.5m, 11 project initiative, will fund a consortium of five industrial and academic partners led by Unilever plc. AmpliPhi says the three year research programme will exploit novel genomic information to develop next generation, specific, natural antimicrobials for use in the personal care industry. “We are pleased to be part of this focused initiative to advance innovative genomic research and development,” says Edward Cappabianca, ceo of AmpliPhi Biosciences. “Our inclusion in this research consortium reflects strongly on the quality of the scientific team that our cso, Dr David Harper, has been building, including Professor Mark Enright, who was instrumental in establishing our credentials and relationship with Unilever. We anticipate that the information we gain during the execution of this project will contribute significantly to our knowledge base of how to develop novel antimicrobial products for the general market, and in turn help to advance our development of human therapeutics to treat bacterial infections.”
